Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases

International Journal of Cancer

Volumn 84, Issue 2, 1999, Pages 192-200

  Re, Gian G ^a   Hazen Martin, Debra J ^a   El Bahtimi, Reem ^a   Brownlee, Noel A ^a   Willingham, Mark C ^b   Garvin, A Julian ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN BCL X;

ANAPLASTIC CARCINOMA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOGENESIS; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; NEPHROBLASTOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTO ONCOGENE; RNA ANALYSIS; TUMOR SUPPRESSOR GENE;

BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, NORTHERN; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; KIDNEY NEOPLASMS; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; WILMS TUMOR;

EID: 0033010683     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990420)84:2<192::AID-IJC17>3.0.CO;2-1     Document Type: Article

References (60)

1. BARDEESY, N., BECKWITH, J.B. and PELLETIER, J., Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 mutations. Cancer Res., 55, 215-219 (1995).
2. BARDEESY, N., FALKOFF, D.F., PETRUZZI, M.-J., NOWAK, N., ZABEL, B., ADOW, M., AGUIR, M.C., GRUNDY, P., SHOWS, S. and PELLETIER, J., Anaplastic Wilms' tumor, a subtype displaying poor prognosis, harbors p53 mutations. Nature (Genet.), 7, 91-97 (1994).
3. BECKWITH, B., ZUPPAN, C.E., BROWNING, N.C., MOKSNESS, J. and BRESLOW, N.E., Histological analysis of aggressiveness and responsiveness in Wilms' tumor. Med. pediatr. Oncol., 27, 422-428 (1996).
4. BENITO, A., SILVA, M., GRILLOT, D., NUÑEZ, G. and FERNANDEZ-LUNA, J.L., Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL. Blood, 87, 3837-3843 (1996).
5. BOISE, L.H., GONZALES-GARCIA, M., DING, L., LINDSTEN, T., TURKA, L.A., MAO, X., NUÑEZ, G. and THOMPSON, C.B., Bcl-X, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74, 597-608 (1993).
6. CALL, K.M., GLASER, T., ITO, C.Y., BUCLER, A.J., PELLETIER, J., HABER, D.A., ROSE, E.A., KRAL, A., YEGER, H., LEWIS, W.H., JONES, C. and HOUSMAN, D.E., Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell, 60, 509-520 (1990).
7. CHAO, D., LINETTE, G.P., BOISE, L.H., WHITE, L.S., THOMPSON, C.B. and KORSMEYER, S.J., Bcl-XL and Bcl-2 repress a common pathway of cell death. J. exp. Med., 182, 821-828 (1995).
8. CHEN, E.H.-Y., LEVINE, B., BOISE, L.H., THOMPSON, C.B. and HARWICK, M., Bax-independent inhibition of apoptosis by Bcl-XL. Nature (Lond.), 379, 554-556 (1996).
9. CHIN, K.V., UEDA, K., PASTAN, I. and GOTTESMAN, M.M., Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science, 255, 459-462 (1992).
10. CHOI, M.S.K., HOLMAN, M., ATKINS, C.J. and KLAUS, G.G.B., Expression of bcl-x during mouse B cell differentiation and following activation by various stimuli. Europ. J. Immunol., 26, 676-682 (1996).
11. CHOMCZYNSKI, P. and SACCHI, N., Single-step method of RNA isolation by acid-guanidinium-thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159 (1987).
12. EL BAHTIMI, R., HAZEN-MARTIN, D.J., RE, G.G., WILLINGHAM, M.C. and GARVIN, A.J., Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors. Mod. Pathol., 9, 238-244 (1996).
13. EL-DEIRY, W.S., KERN, S.E., PIETEMPOL, J.A., KINZLER, K.W. and VOGELSTEIN, B., Definition of a consensus binding site for p53. Nature (Genet.), 1, 45-49 (1992).
14. FANG, W., RIVARD, J.J., MUELLER, D.L. and BEHRENS, T.W., Cloning and molecular characterization of mouse bcl-X in B and T lymphocytes. J. Immunol., 153, 4388-4398 (1994).
15. FARIA, P., BECKWITH, B., MISHRA, K., ZUPPAN, C., WEEKS, D.A., BRESLOW, N. and GREEN, D.M., Focal versus diffuse anaplasia in Wilms' tumor. New definition with prognostic significance. Amer. J. surg. Pathol., 20, 909-920 (1996).
16. FEARON, E.R. and VOGELSTEIN, B.A., Genetic model for colorectal tumorigenesis. Cell, 61, 759-767 (1990).
17. FEINBERG, A.P. and VOGELSTEIN, B.A., Technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem., 132, 6-13 (1983).
18. FIELDS, S. and JANG, S.K., Presence of a potent transcription activating sequence in the p53 protein. Science, 249, 1046-1049 (1990).
19. FINLAY, C.A., HINDS, P.W. and LEVINE, A.J., The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57, 1083-1093 (1989).
20. GINSBERG, D., MECHTA, F., YANIV, M. and OREN, M., Wild-type p53 can down-modulate the activity of various promoters. Proc. nat. Acad. Sci. (Wash.), 88, 9979-9983 (1991).
21. GONZALES-GARCIA, M., GARCIA, I., DING, L., O'SHEA, S., BOISE, L.H., THOMPSON, C.B. and NUÑEZ, G., Bcl-X is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death. Proc. nat. Acad. Sci. (Wash.), 92, 4304-4308 (1995).
22. GONZALES-GARCIA, M., PEREZ-BALLESTERO, R., DING, L., DUAN, L., BOISE, L.H., THOMPSON, C.B. and NUÑEZ, G., Bcl-XL is the magior Bcl-X mRNA form expressed during murine development and its product localizes to mitochondria. Development, 120, 3033-3042 (1994).
23. GREEN, D.M. and 13 OTHERS, Treatment of children with stage II and IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J. clin. Oncol., 12, 2126-2213 (1994).
24. HABER, D.A., PARK, S., MAHESWARAN, S., ENGLERT, C., RE, G.G., HAZEN-MARTIN, D.J., SENS, D.A. and GARVIN, A.J., WT1-mediated growth suppression of Wilms' tumor cells expressing a WT1 splicing variant. Science, 262, 2057-2059 (1993).
25. HALDAR, S., NEGRINI, M., MONNE, M., SABBIONI, S. and CROCE, C.M., Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54, 2095-2097 (1994).
26. HAZEN-MARTIN, D.J., RE, G.G., GARVIN, A.J. and SENS, D.A., Distinctive properties of an anaplastic tumor and its associated cell line. Amer. J. Pathol., 144, 1023-1034 (1994).
27. HEWITT, S.M., HAMADA, S., MCDONNELL, T.J., RAUSCHER III, F.J. and SAUNDERS, G.F., Regulation of the proto-oncogenes Bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res., 55, 5386-5389 (1995).
28. HOCKENBERY, D., NUÑEZ, G., MILLIMAN, C., SCHREIBER, R.D. and KORSMEYER, S.J., Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348, 334-346 (1990).
29. JOENSUU, H., PYKKANEN, L. and TOLKKANEN, S., Bcl-2 protein expression and long-term survival in breast cancer. Amer. J. Pathol., 145, 1191-1198 (1994).
30. KRAJEWSKA, M., MOSS, S.F., KRAJEWSKI, S., SONG, K., HOLT, P.R. and REED, J.C., Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinoma. Cancer Res., 56, 2422-2427 (1996).
31. LAEMMLI, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227, 280-285 (1970).
32. LEEK, R.D., KAKLAMANIS, L., PEZZELLA, F., GATTER, K.C. and HARRIS, A.L., bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor-negative tumours and in situ cancer. Brit. J. Cancer, 69, 135-139 (1994).
33. LEVINE, A.J., MOMAND, J. and FINLAY, C.A., The p53 tumor suppressor gene. Nature (Lond.), 351, 453-456 (1991).
34. LIANG, X.H., MUNGAL, S., AYSCUE, A., MEISSNER, J.D., WODNICKI, P., HOCKENBERY, D., LOCKETT, S. and HERMAN, B., Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J. cell. Biochem., 57, 509-521 (1995).
35. MALKIN, D., SEXSMITH, E., YEGER, H., WILLIAMS, B.R. and COPPES, M.J. Mutations of the p53 gene occur infrequently in Wilms' tumor. Cancer Res., 54, 2077-2079 (1994).
36. MIYASHITA, T., HARIGAI, M., HANADA, M. and REED, J.C., Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res, 54, 3131-3135 (1994a).
37. MIYASHITA, T., KRAJEWSKI, S., KRAJEWSKA, M., WANG, H.G., LIN, H.K., LIEBERMAN, D.A., HOFFMAN, B. and REED, J.C., Tumor suppressor p53 is a regulator of bcl2 and bax gene expression in vitro and in vivo. Oncogene, 9, 1799-1805 (1994b).
38. NGYEN, K.T., LIU, B., UEDA, K., GOTTESMAN, M.M., PASTAN, I. and CHIN, K.V., Transactivation of the human multidrug resistance (MDRI) gene promoter by p53 mutants. Oncol. Res., 6, 71-77 (1994).
39. OESTERLING, J.E., EGGLESTON, J.C., JEFFS, R.D. and LEVENTHAL, B.G., Anaplastic sarcoma in a mature metachronous bilateral Wilms' tumor after irradiation and chemotherapy. Cancer, 59, 2000-2005 (1987).
40. OLTVAI, Z.N., MILLIMAN, C.L. and KORSMEYER, S.J., Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609-619 (1993).
41. PARK, S., BERNARD, A., BOVE, K.E., SENS, D.A., HAZEN-MARTIN, D.J., GARVIN, A.J. and HABER, D.A., Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumor. Nature (Genet.), 5, 363-367 (1993).
42. PEZZELLA, P., MORRISON, H., JONES, M., GATTER, K.C., LANE, D., HARRIS, A.L. and MASON, D.Y., Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin lymphoma. Histopathotogy, 22, 39-44 (1993).
43. RAYCROFT, L., WU, H. and LOZANO, G., Transcriptional activation by wild-type but not transforming mutant of the p53 anti-oncogene. Science, 249, 1049-1051 (1990).
44. RE, G.G., ANTOUN, G.R. and ZIFF, T.F., Modulation of a constitutive transcriptional block at exon-1 controls human c-myc expression. Oncogene, 5, 1247-1250 (1990).
45. RE, G.G., WILLINGHAM, M.C., EL BAHTIMI, R., BROWNLEE, N.A., HAZEN-MARTIN, D.J. and GARVIN, A.J., Anaplasia and drug selection-independent over-expression of the multidrug resistance gene MDR1 in Wilms' tumor. Mod. Pathol., 10, 129-136 (1997).
46. SELDAK, T.W., OLTVAI, Z.N., YANG, E., WANG, K., BOISE, L.H., THOMPSON, C.B. and KORSMEYER, S.J., Multiple Bcl-2 family members demonstrate selective dimerization with Bax. Proc. nat. Acad. Sci. (Wash.), 92, 7834-7838 (1995).
47. SILVESTRINI, R., VERONESI, S., DAIDONE, M.G., BENINI, E., BORACCHI, P., MEZZETTI, M., DI FRONZO, G., RILKE, F. and VERONESI, U., The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. nat. Cancer Inst., 86, 499-504 (1994).
48. SINICROPE, F.A., HART, J., MICHELASSI, F. and LEE, J., Prognostic value of BCl-2 oncoprotein expression in stage II colon carcinoma. Cancer Res., 1, 1103-1110 (1995).
49. SORENSON, C.M., ROGERS, S.A., KORSMEYER, S.J. and HAMMERMAN, M.R., Fulminant metanephric apoptosis and abnormal kidney development in Bcl-2-deficient mice. Amer. J. Physiol., 268, 73-81 (1995).
50. TAKEUCHI, S., BARTRAM, C.R., LUDWIG, R., ROYER-POKORA, B., SCHNEIDER, S., IMAMURA, J. and KORFFLER, H.P., Mutations of p53 in Wilms' tumors. Mod. Pathol., 8, 483-487 (1995).
51. TILLY, J.L., TILLY, K.I., KENTON, M.L. and JOHNSON, A.L., Expression of members of the Bcl-2 gene family in the immature rat ovary: equine chorionic gonadotropin-mediated inhibition of granulosa cell apoptosis is associated with decreased Bax and constitutive Bcl-2 and Bcl-Xlong messenger ribonucleic acid levels. Endocrinology, 136, 232-241 (1995).
52. TSUJIMOTO, Y., COSSMAN, J., JAFFE, E. and CROCE, C.M., Involvement of the bcl-2 gene in human follicular lymphoma. Science, 228, 1440-1443 (1985).
53. TSUJIMOTO, Y., FINGER, L.R., YUNIS, J., NOWEL, P.C. and CROCE, C.M., Cloning of the chromosome breakpoint of neoplastic B cell with the t(14;18) chromosome translocation. Science, 226, 1097-1099 (1984).
54. VEIS, D.J., SORENSON, C.M., SHUTTER, J.R. and KORSMEYER, S.J., Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell, 75, 229-240 (1993).
55. VEIS NOVACK, D.J. and KORSMEYER, S.J., Bcl-2 protein expression during murine development. Amer. J. Pathol., 145, 61-73 (1994).
56. WEINTRAUB, H., HAUSCHKA, S. and TAPSCOTT, S.J., The MCK enhancer contains a p53 responsive element. Proc. nat. Acad. Sci. (Wash.), 88, 4570-4571 (1991).
57. WILSON, W.H., TERUYA-FELDSTEIN, J., FEST, T., HARRIS, C., STEINBERG, S.M., JAFFE, E.S. and RAFFELD, M., Relationship of p53, Bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood, 89, 601-609 (1997).
58. YANG, X.-F., WEBER, G.F. and CANTOR, H., A novel Bcl-X isoform connected to the T cell receptor regulates apoptosis in T cells. Immunity, 7, 529-539 (1997).
59. YUNIS, J., MAYER, M.G., ARNESEN, M.A., AEPPLI, D.P., OKEN, M.M. and FRIZZERA, G., bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N. Engl. J. Med, 320, 1047-1054 (1989).
60. ZHANG, L., KASHANCHI, F., ZHAN, Q., ZHAN, S., BRADY, J.N., FORNACE, A.J. and SETH, P., Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Res., 56, 1367-1373 (1996).